Literature DB >> 26893727

Novel cyclic pentapeptide H-15 induces differentiation and inhibits proliferation in murine melanoma B16 cells.

Yunjiang Liu1, Geng Zhang2, Haoqi Wang2, Shouxin Liu3, Jinxia Chen2, Lianmei Zhao2, Jie Li1, Baoen Shan2.   

Abstract

Sansalvamide A is a cyclic depsipeptide that is isolated from a marine fungus of the Fusarium genus. Sansalvamide A exhibits significant antitumor ability. The molecular formula and molecular weight of the novel sansalvamide A derivative H-15 are C29H44BrN5O6 and 637.2475, respectively. In the present study, H-15 was found to inhibit the proliferation and induce the differentiation of murine melanoma B16 cells. A sulforhodamine B colorimetric assay was used to measure the inhibitory effects of 0.1, 1, 10, 50 and 100 µM H-15 on the B16 cells, and the results revealed that the inhibitory effects of H-15 exerted on the B16 cells occurred in a concentration-dependent manner. In addition, the growth curve model of the B16 cells treated with 50 µM H-15 revealed that the effect of H-15 was also time-dependent. The differentiation morphology of the B16 cells was observed subsequent to treating the cells with H-15. An optical microscope was used to observe the differentiation morphology of the cells. In addition, melanin secretion increased in the B16 cells treated with 50 µM H-15. The expression levels of tyrosinase (TYR) were assayed by western blot analysis, and it was found that the cells treated with 50 µM H-15 for 48 h exhibited increased expression of TYR. The results of the present study indicated that H-15 may induce the differentiation of B16 cells.

Entities:  

Keywords:  B16 cells; differentiation; sansalvamide A; tyrosinase

Year:  2015        PMID: 26893727      PMCID: PMC4734122          DOI: 10.3892/ol.2015.4025

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  12 in total

1.  All-trans retinoic acid loaded block copolymer nanoparticles efficiently induce cellular differentiation in HL-60 cells.

Authors:  Manu D Tiwari; Sarika Mehra; Sameer Jadhav; Jayesh R Bellare
Journal:  Eur J Pharm Sci       Date:  2011-10-28       Impact factor: 4.384

Review 2.  Radiation therapy as primary and adjuvant treatment for local and regional melanoma.

Authors:  Lawrence B Berk
Journal:  Cancer Control       Date:  2008-07       Impact factor: 3.302

Review 3.  Absorption of peptide and peptidomimetic drugs.

Authors:  G L Amidon; H J Lee
Journal:  Annu Rev Pharmacol Toxicol       Date:  1994       Impact factor: 13.820

4.  N-methylsansalvamide a peptide analogues. Potent new antitumor agents.

Authors:  Shouxin Liu; Wenxin Gu; Denise Lo; Xian-Zhong Ding; Michael Ujiki; Thomas E Adrian; Gerald A Soff; Richard B Silverman
Journal:  J Med Chem       Date:  2005-05-19       Impact factor: 7.446

Review 5.  Differentiation therapy of human cancer: basic science and clinical applications.

Authors:  M Leszczyniecka; T Roberts; P Dent; S Grant; P B Fisher
Journal:  Pharmacol Ther       Date:  2001 May-Jun       Impact factor: 12.310

6.  Synthesis of Sansalvamide A derivatives and their cytotoxicity in the MSS colon cancer cell line HT-29.

Authors:  Thomas J Styers; Ahmet Kekec; Rodrigo Rodriguez; Joseph D Brown; Julia Cajica; Po-Shen Pan; Emily Parry; Chris L Carroll; Irene Medina; Ricardo Corral; Stephanie Lapera; Katerina Otrubova; Chung-Mao Pan; Kathleen L McGuire; Shelli R McAlpine
Journal:  Bioorg Med Chem       Date:  2006-05-11       Impact factor: 3.641

7.  Sansalvamide induces pancreatic cancer growth arrest through changes in the cell cycle.

Authors:  Michael J Heiferman; Mohammad R Salabat; Michael B Ujiki; Matthew J Strouch; Eric C Cheon; Richard B Silverman; David J Bentrem
Journal:  Anticancer Res       Date:  2010-01       Impact factor: 2.480

8.  Inhibition of c-Myc down-regulation by sustained extracellular signal-regulated kinase activation prevents the antimetabolite methotrexate- and gemcitabine-induced differentiation in non-small-cell lung cancer cells.

Authors:  Jordi M Serra; Antonio Gutiérrez; Regina Alemany; María Navarro; Teresa Ros; Carlos Saus; Jordi Ginés; Antonia Sampol; Juan Carlos Amat; Lorenzo Serra-Moisés; Javier Martín; Antonio Galmés; Oliver Vögler; Joan Besalduch
Journal:  Mol Pharmacol       Date:  2008-03-19       Impact factor: 4.436

Review 9.  Melanoma biology and new targeted therapy.

Authors:  Vanessa Gray-Schopfer; Claudia Wellbrock; Richard Marais
Journal:  Nature       Date:  2007-02-22       Impact factor: 49.962

10.  A novel cyclic pentapeptide, H-10, inhibits B16 cancer cell growth and induces cell apoptosis.

Authors:  Geng Zhang; Shouxin Liu; Yunjiang Liu; Feifei Wang; Jingwen Ren; Jifeng Gu; Kaixuan Zhou; Baoen Shan
Journal:  Oncol Lett       Date:  2014-05-08       Impact factor: 2.967

View more
  5 in total

Review 1.  Heat Shock Protein 90 (HSP90) Inhibitors as Anticancer Medicines: A Review on the Computer-Aided Drug Discovery Approaches over the Past Five Years.

Authors:  Ayanda M Magwenyane; Samuel C Ugbaja; Daniel G Amoako; Anou M Somboro; Rene B Khan; Hezekiel M Kumalo
Journal:  Comput Math Methods Med       Date:  2022-05-31       Impact factor: 2.809

2.  A LY-15, a novel cyclic pentapeptide that inhibits B16 cell proliferation and migration and induces cell apoptosis.

Authors:  Xuan Wang; Xiangli Yao; Shiming Fan; Chenshuang Xiang; Runjiao Liu; Juan Feng; Jing Huang; Shouxin Liu
Journal:  Oncol Lett       Date:  2018-02-12       Impact factor: 2.967

3.  Yessotoxin, a Marine Toxin, Exhibits Anti-Allergic and Anti-Tumoural Activities Inhibiting Melanoma Tumour Growth in a Preclinical Model.

Authors:  Araceli Tobío; Amparo Alfonso; Iris Madera-Salcedo; Luis M Botana; Ulrich Blank
Journal:  PLoS One       Date:  2016-12-14       Impact factor: 3.240

4.  18F-labeled Dimer-Sansalvamide A Cyclodecapeptide: A Novel Diagnostic Probe to Discriminate Pancreatic Cancer from Inflammation in a Nude Mice Model.

Authors:  Xiaohui Wang; Jun Zhang; Zhijian Han; Liheng Ma; Yumin Li
Journal:  J Cancer       Date:  2022-03-21       Impact factor: 4.207

Review 5.  Inhibitors of HSP90 in melanoma.

Authors:  Aleksandra Mielczarek-Lewandowska; Mariusz L Hartman; Malgorzata Czyz
Journal:  Apoptosis       Date:  2020-02       Impact factor: 4.677

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.